Related Experiment Video

Updated: Aug 19, 2026

Rat Model of Right-Sided Cardiac Remodeling and Arrhythmia Using Pulmonary Artery Banding
10:39

Rat Model of Right-Sided Cardiac Remodeling and Arrhythmia Using Pulmonary Artery Banding

Published on: August 30, 2024

[Beta blockers in the treatment of heart failure due to left ventricular systolic dysfunction]

Abdoul Kane1

  • 1Faculté de Médecine, Pharmacie, Odontostomatologie, Université Cheikh Anta Diop de Dakar.

Dakar Medical
|March 22, 2005
PubMed

Insights

Beta-blockers effectively treat heart failure by counteracting sympathetic effects on the heart. Safe use requires adherence to contraindications and gradual dosage adjustments for optimal patient outcomes.

Area of Science:

  • Cardiology
  • Pharmacology

Context:

  • Heart failure with left ventricular systolic dysfunction is a significant clinical challenge.
  • Sympathetic nervous system overactivity negatively impacts myocardial function and structure.

Purpose:

  • To review the established role of beta-blockers in managing heart failure.
  • To highlight the benefits and safety considerations for beta-blocker therapy.

Summary:

  • Beta-blockers counteract detrimental sympathetic effects on the myocardium, including hypertrophy, fibrosis, and apoptosis.
  • Major clinical trials (CIBIS-II, MERIT-HF, CAPRICORN) demonstrate that specific beta-blockers (Bisoprolol, Metoprolol, Carvedilol) reduce heart failure hospitalizations, improve function, and increase survival in NYHA class II-IV patients.
  • Safe initiation and titration of beta-blockers are crucial, respecting contraindications and clinical stability.

Impact:

  • Beta-blocker therapy is a cornerstone in heart failure management, improving patient prognosis.
  • Understanding contraindications and proper dosing strategies is essential for maximizing therapeutic benefits and minimizing risks.
  • This evidence supports guideline-directed medical therapy for heart failure patients.

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...